OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
The OncLive Insider app is live!CME Opportunities
Specialty
View MoreBreast CancerLung CancerGastrointestinal CancerGenitourinary CancersOvarian CancerProstate CancerMelanoma & Skin CancerMCLMPNCAR T-cell TherapyChronic Lymphocytic LeukemiaGynecologic OncologyHematologic OncologyImmuno-OncologyMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
PartnersPublications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker ConsortiumSubscribe
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • The OncLive Insider app is live!
  • CME Opportunities
SpecialtySee All >
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Ovarian Cancer
  • Prostate Cancer
  • Melanoma & Skin Cancer
  • MCL
  • MPN
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gynecologic Oncology
  • Hematologic Oncology
  • Immuno-Oncology
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

John K. Lee, MD, PhD

  1. home

Articles

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Dr Lee on the Significance of the Tumor-Agnostic Approval of T-DXd for HER2+ Urothelial Cancer

October 16th 2024

John K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.

Dr Lee on Safety Considerations for Enfortumab Vedotin in Metastatic Urothelial Cancer

September 27th 2024

John K. Lee, MD, PhD, discusses safety considerations for enfortumab vedotin in the treatment of metastatic urothelial cancer.

Dr Lee on Treatment Considerations for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

September 5th 2024

John K. Lee, MD, PhD, discusses treatment considerations for the use of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.